{"id":"W4297983491","doi":"10.1007/s12032-022-01772-2","title":"RETRACTED ARTICLE: TNFR2 antagonist and agonist: a potential therapeutics in cancer immunotherapy","year":2022,"lang":"en","type":"review","venue":"Medical Oncology","topic":"Immune cells in cancer","field":"Immunology and Microbiology","cited_by":8,"is_retracted":true,"has_abstract":false,"ca_institutions":"Emergent BioSolutions (Canada)","funders":"","keywords":"FOXP3; Cancer research; Cancer; Immunology; Cancer immunotherapy; Agonist; Immunotherapy; Immunopharmacology; Medicine; Tumor necrosis factor alpha; Effector; Downregulation and upregulation; Receptor; Pharmacology; Biology; Internal medicine; Immune system","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002639868,0.001304542,0.001949045,0.002191928,0.0008395039,0.002289421,0.002142564,0.005938527,0.01008804],"category_scores_gemma":[0.005863267,0.000425733,0.001131851,0.001503966,0.001399331,0.002681904,0.00156501,0.006154266,0.008807928],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001429496,"about_ca_system_score_gemma":0.00254469,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001261909,"about_ca_topic_score_gemma":0.002864352,"domain_scores_codex":[0.9986364,0.0002201193,0.0002322386,0.0001466891,0.0005986854,0.000165838],"domain_scores_gemma":[0.9973438,0.0008564746,0.0002868729,0.00007576602,0.001082097,0.0003550559],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0001674545,0.00002974778,0.00009021507,0.002695605,0.00004918596,0.0006043875,0.00004264662,0.0001098246,0.0008523746,0.001526778,0.8484822,0.1453495],"study_design_scores_gemma":[0.00005161843,0.0001111457,0.0002304086,0.0007523854,0.00007117808,0.001242629,0.00002464301,0.0000654309,0.0004013208,0.0007339649,0.9962988,0.00001654179],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"editorial","genre_gemma":"review","genre_scores_codex":[0.0003833867,0.4004245,0.0008767736,0.04488947,0.5486262,0.00004545916,0.0002792975,0.00009859038,0.004376207],"genre_scores_gemma":[0.004677549,0.4638574,0.001301184,0.1168083,0.3678011,0.00006368106,0.0005921561,0.0000897796,0.04480882],"genre_candidate":"review","genre_consensus":null,"teacher_disagreement_score":0.01008804,"threshold_uncertainty_score":0.03374791,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04576020982365012,"score_gpt":0.376376725439356,"score_spread":0.3306165156157058,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}